ResearchMoz added Latest Research Report titled " Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline " to it's Large Report database.
Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.
Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=903617
The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.
The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.
Scope
Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.
Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=903617
The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.
The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.
Scope
- The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- What effect will the patent expirations of currently branded therapies have on market value?
Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 14
2.5.2 Automated Office Blood Pressure Measurement 14
2.5.3 Ambulatory Blood Pressure Monitoring 15
2.5.4 Home Blood Pressure Monitoring 15
2.5.5 Miscellaneous Methods 15
2.5.6 Diagnosis of Target Organ Damage 15
2.5.7 Diagnosis of Hypertension in Pregnancy 15
2.6 Prognosis 16
2.7 Disease Stage 17
2.8 Treatment Options 17
2.8.1 Treatment Algorithm 17
2.8.2 Pharmacological Treatment 18
2.8.3 Non-pharmacological Treatment 22
3 Marketed Products 24
3.1 Angiotensin II Receptor Antagonists 24
3.1.1 Losartan - Merck & Co 24
3.1.2 Olmesartan - Daiichi Sankyo 26
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo 27
3.1.4 Valsartan - Novartis 28
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 14
2.5.2 Automated Office Blood Pressure Measurement 14
2.5.3 Ambulatory Blood Pressure Monitoring 15
2.5.4 Home Blood Pressure Monitoring 15
2.5.5 Miscellaneous Methods 15
2.5.6 Diagnosis of Target Organ Damage 15
2.5.7 Diagnosis of Hypertension in Pregnancy 15
2.6 Prognosis 16
2.7 Disease Stage 17
2.8 Treatment Options 17
2.8.1 Treatment Algorithm 17
2.8.2 Pharmacological Treatment 18
2.8.3 Non-pharmacological Treatment 22
3 Marketed Products 24
3.1 Angiotensin II Receptor Antagonists 24
3.1.1 Losartan - Merck & Co 24
3.1.2 Olmesartan - Daiichi Sankyo 26
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo 27
3.1.4 Valsartan - Novartis 28
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment